Stock NBSE NEUBASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NeuBase Therapeutics, Inc. Nasdaq

Equities

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
0.378 USD -3.20% Intraday chart for NeuBase Therapeutics, Inc. -.--% -48.93%
May. 29 NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding CI

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023
Capitalization 1 81.25 146.8 102.1 12.06 1.278
Enterprise Value (EV) 1 81.25 146.8 102.1 12.06 1.278
P/E ratio - - - - -
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA - - - - -
EV / FCF -24,617,554 x - - - -
FCF Yield -0% - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 854 1,156 1,636 1,613 3,752
Reference price 2 95.20 127.0 62.40 7.480 0.3406
Announcement Date 1/9/20 12/23/20 12/23/21 12/21/22 -
1EUR in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -26.34 -17.07 -26.57 -33.32 -14.01
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -26.96 -17.38 -25.41 -33.78 -12.32
Net income 1 -26.96 -17.38 -25.41 -33.78 -12.32
Net margin - - - - -
EPS - - - - -
Free Cash Flow -3.301 - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 1/9/20 12/23/20 12/23/21 12/21/22 -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow -3.3 - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 0.46 - - - 1.2
Capex / Sales - - - - -
Announcement Date 1/9/20 12/23/20 12/23/21 12/21/22 -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+51.85% 57.87B
LONZA GROUP AG Stock Lonza Group AG
+41.22% 40.25B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.25% 39.94B
CELLTRION, INC. Stock Celltrion, Inc.
-5.16% 28.54B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.79% 26.4B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.18% 19.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.88% 12.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.61% 12.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.06% 12.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. O7P Stock
  4. NBSE Stock
  5. Financials NeuBase Therapeutics, Inc.